BACKGROUND: There is a paucity of data on the effects of adherence to treatment on outcomes for patients with acute heart failure (HF) in Korea. We used HF performance measures to evaluate overall adherence and whether this affects clinical outcomes. METHODS AND RESULTS: Among 3,466 patients in the Korean Heart Failure Registry, 1,527 patients with left ventricular systolic dysfunction (LVSD) who survived hospitalization were evaluated. Modified validated performance measures were defined as follows: use at discharge of angiotensin-converting enzyme inhibitor (ACEI), angiotensin-receptor II blocker (ARB), β-blocker or aldosterone receptor antagonist. Adherence to performance measures were as follows: ACEI or ARB at discharge, 68.0%; β-blocker at discharge, 40.9%; aldosterone receptor antagonist at discharge, 37.5%. On multivariate analysis, adherence to the measure of ACEI or ARB use at discharge was significantly associated with mortality (odds ratio (OR), 0.344; 95% confidence interval (CI), 0.123-0.964), readmission (OR, 0.180; 95%CI, 0.062-0.522) and mortality/readmission (OR, 0.297; 95%CI, 0.125-0.707) at 60 days and that for β-blocker with mortality (OR, 0.337; 95%CI, 0.147-0.774) at 1 year. CONCLUSIONS: For patients with LVSD in Korea, adherence to treatment performance measures, including prescription of an ACEI/ARB and β-blocker use at discharge, is associated with improved clinical outcomes.
BACKGROUND: There is a paucity of data on the effects of adherence to treatment on outcomes for patients with acute heart failure (HF) in Korea. We used HF performance measures to evaluate overall adherence and whether this affects clinical outcomes. METHODS AND RESULTS: Among 3,466 patients in the Korean Heart Failure Registry, 1,527 patients with left ventricular systolic dysfunction (LVSD) who survived hospitalization were evaluated. Modified validated performance measures were defined as follows: use at discharge of angiotensin-converting enzyme inhibitor (ACEI), angiotensin-receptor II blocker (ARB), β-blocker or aldosterone receptor antagonist. Adherence to performance measures were as follows: ACEI or ARB at discharge, 68.0%; β-blocker at discharge, 40.9%; aldosterone receptor antagonist at discharge, 37.5%. On multivariate analysis, adherence to the measure of ACEI or ARB use at discharge was significantly associated with mortality (odds ratio (OR), 0.344; 95% confidence interval (CI), 0.123-0.964), readmission (OR, 0.180; 95%CI, 0.062-0.522) and mortality/readmission (OR, 0.297; 95%CI, 0.125-0.707) at 60 days and that for β-blocker with mortality (OR, 0.337; 95%CI, 0.147-0.774) at 1 year. CONCLUSIONS: For patients with LVSD in Korea, adherence to treatment performance measures, including prescription of an ACEI/ARB and β-blocker use at discharge, is associated with improved clinical outcomes.
Authors: Lisa C Bratzke; Debra K Moser; Michele M Pelter; Steven M Paul; Thomas S Nesbitt; Lawton S Cooper; Kathleen A Dracup Journal: J Cardiovasc Nurs Date: 2016 Jan-Feb Impact factor: 2.083
Authors: W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges Journal: Clin Res Cardiol Date: 2014-07-23 Impact factor: 5.460
Authors: Claudia Fischer; Hester F Lingsma; Perla J Marang-van de Mheen; Dionne S Kringos; Niek S Klazinga; Ewout W Steyerberg Journal: PLoS One Date: 2014-11-07 Impact factor: 3.240
Authors: Min Soo Ahn; Byung Su Yoo; Junghan Yoon; Seung Hwan Lee; Jang Young Kim; Sung Gyun Ahn; Young Jin Youn; Jun Won Lee; Jung Woo Son; Hye Sim Kim; Dae Ryong Kang; Sang Eun Lee; Hyun Jai Cho; Hae Young Lee; Eun Seok Jeon; Seok Min Kang; Dong Ju Choi; Myeong Chan Cho Journal: J Korean Med Sci Date: 2019-05-06 Impact factor: 2.153